Asset / Drug
Drug and asset intelligence for Tislelizumab with 12 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
PD-1 Inhibitor
A Phase III trial is underway to compare the efficacy of TACE plus tislelizumab and lenvatinib against GEMCIS plus tislelizumab in patients with unresectable intrahepatic cholangiocarcinoma.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.